Paediatric care

Momentum in the Pediatric Tuberculosis Treatment Pipeline

Other short reports from BHIVA:

Elvitegravir in children and adolescents

Point of care HIV PCR test for infant diagnosis: good performance but poorer results in youngest age group

Weekend-off ART is non-inferior to continuous ART in young people taking efavirenz-based regimens: results from BREATHER study

Increased cardiovascular risks in HIV positive children in Uganda and Zambia partially reversed by ART

Lopinavir/ritonavir superior to nevirapine in children <3 years old: IMPAACT P1060 five year results

Long-term safety and efficacy of tenofovir in children

Drug resistance in children after PMTCT and early treatment

Pharmacokinetics and safety of moxifloxacin in children

TB in the ARROW trial of children on ART

Problems giving current second line TB drugs to children

Infants start ART too late but improvement over time in Southern Africa

Update on paediatric antiretrovirals

Is d4T a viable option for children in low-income countries?

3TC or FTC monotherapy suboptimal as a bridging strategy for adolescents

Rationalising the paediatric antiretroviral formulary in Malawi

Time to first-line failure in the IeDEA cohort

Influence of early ART on antibody detection in children

Wrestling with the implications of the Mississippi case

The paediatric antiretroviral pipeline

Playing catch-up: paediatric tuberculosis treatment pipeline

Once daily lopinavir/ritonavir not recommended for routine use in children and adolescents

Early antiretroviral treatment in infants

Catching up with pathogenesis and cure research from CROI 2014

Paediatric pipeline: CROI 2014 update on new antiretrovirals for children

Efavirenz maintenance therapy effective in children exposed to nevirapine prophylaxis

FDA approves raltegravir for children older than 4 weeks

Lower immune response to the qHPV vaccine in HIV positive girls

HIV exposed vs unexposed babies have lower gestational age and birth weight in Danish study

Outcomes in infants exposed to lopinavir/ritonavir in utero

Preventing and treating TB in children – more baby steps

Paediatric guidelines on the prevention and treatment of OIs (November 2013)

WHO 2013 guidelines: what about the missing formulations?

Decreased growth in ART exposed uninfected infants in Botswana

Antiretrovirals, doses and formulations for children

The paediatric antiretroviral pipeline

Population pharmacokinetics of efavirenz to inform dosing in children three months of age and above

Bilirubin as a surrogate marker for atazanavir in children

EU approval for raltegravir in children aged 2 years and older

FDA update label for paediatric efavirenz and capsule sprinkle formulation

Five-year results from the AntiRetroviral Research for Watoto (ARROW) Trial

Comparison of ritonavir-boosted lopinavir or NNRTI ART and PK with antimalarials in Ugandan children

Pharmacokinetics and acceptability of lopinavir/ritonavir sprinkles in children aged 1 to 4 years

Pharmacokinetics of currently available antiretroviral options for young children

Tenofovir use in children

ddI resistance in South African children failing an abacavir or d4T based first-line regimen

Report of a functional cure in an HIV infected infant

Once-daily option for paediatric use of darunavir/ritonavir

Paediatric TB: glimpses of PK data and a potential new approach to drug development

New UNITAID grants focus on paediatric HIV, TB and malaria

The American Academy of Pediatrics recommends that HIV positive mothers not breastfeed their infants, regardless of maternal viral load and ART

US paediatric guidelines updated (November 2012)

Resistance in infants and children receiving ART in South Africa

ART and adverse birth outcomes in Botswana

Antiviral activity in vitro with S/GSK1265744

Paediatrics studies at 19th International AIDS Conference and the 4th International Workshop on HIV Pediatrics

Novel lopinavir/ritonavir sprinkle formulation for children in resource-limited settings

Update on new antiretrovirals for children and adolescents

Tenofovir prophylaxis for neonates

Efavirenz levels variable in children in the CHAPAS-3 study

Early initiation of ART is associated with growth recovery in children in NEVEREST-2

High prevalence of peripheral neuropathy in children taking d4T in rural South Africa

Lipid profile in children in PREDICT: immediate versus deferred nevirapine-based ART

Paediatric formulations of ARVs: including an exciting new class

Post navigation